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Abstract Glutamate is the most abundant free amino acid
in the brain and is at the crossroad between multiple met-
abolic pathways. Considering this, it was a surprise to
discover that glutamate has excitatory effects on nerve
cells, and that it can excite cells to their death in a process
now referred to as ‘‘excitotoxicity’’. This effect is due to
glutamate receptors present on the surface of brain cells.
Powerful uptake systems (glutamate transporters) prevent
excessive activation of these receptors by continuously
removing glutamate from the extracellular fluid in the
brain. Further, the blood–brain barrier shields the brain
from glutamate in the blood. The highest concentrations of
glutamate are found in synaptic vesicles in nerve terminals
from where it can be released by exocytosis. In fact, glu-
tamate is the major excitatory neurotransmitter in the
mammalian central nervous system. It took, however, a
long time to realize that. The present review provides a
brief historical description, gives a short overview of glu-
tamate as a transmitter in the healthy brain, and comments
on the so-called glutamate–glutamine cycle. The glutamate
transporters responsible for the glutamate removal are
described in some detail.
Keywords Glutamate uptake  EAAT2  EAAT1 
EAAT3  slc1a2  slc1a1  slc1a3  Glutamate  Glutamate






CNS Central nervous system
EAAC1 Glutamate transporter number 3 (EAAT3;
slc1a1; Kanai and Hediger 1992)
EAAT Excitatory amino acid transporter (synonymous
to glutamate transporter)
GABA c-Aminobutyric acid
GLAST Glutamate transporter number 1 (EAAT1;
slc1a3; Storck et al. 1992; Tanaka 1993a)
GLT-1 Glutamate transporter number 2 (EAAT2;





Outside the community of biomedical scientists, glutamate
is probably best known as ‘‘monosodium glutamate’’ or
‘‘MSG’’ which is the sodium salt of glutamic acid and a
white crystalline solid used as a flavor or taste enhancer in
food (food additive number E620). This, however, is not
the reason for the enormous scientific interest in glutamate.
The main motivation for the ongoing worldwide research
on glutamate is that glutamate is the major excitatory
transmitter in the brain.
Like other signaling substances, the signaling effect of
glutamate is not dependent on the chemical nature of
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glutamate, but on how cells are programmed to respond
when exposed to it. Because the glutamate receptor pro-
teins are expressed on the surface of the cells in such a way
that they can only be activated from the outside, it follows
that glutamate exerts its neurotransmitter function from the
extracellular fluid. Consequently, control of receptor acti-
vation is achieved by releasing glutamate to the extracel-
lular fluid and then removing glutamate from it. Because
there are no enzymes extracellularly that can degrade
glutamate, low extracellular concentrations require cellular
uptake. This uptake is catalyzed by a family of transporter
proteins located at the cell surface of both astrocytes and
neurons (e.g. Danbolt 2001; Grewer and Rauen 2005;
Tzingounis and Wadiche 2007; Vandenberg and Ryan
2013).
Because glutamate is the major mediator of excitatory
signals as well as of nervous system plasticity, including
cell elimination, it follows that glutamate should be present
at the right concentrations in the right places at the right
time. It further follows that cells should have the correct
sensitivity to glutamate and have energy enough to with-
stand normal stimulation, and that glutamate should be
removed with the appropriate rates from the right locations.
Both too much glutamate and too little glutamate are
harmful. Excessive activation of glutamate receptors may
excite nerve cells to their death in a process now referred to
as ‘‘excitotoxicity’’. This toxicity was initially perceived as
a paradox like ‘‘Dr. Jekyll and Mr. Hyde’’, but it is now
clear that glutamate is toxic, not in spite of its importance,
but because of it. As outlined before (Danbolt 2001), the
intensity of glutamatergic stimulation that a given cell can
tolerate, depends on several factors. As long as one vari-
able is not extreme, it will be the combination of several
factors that will determine the outcome.
It took a long time to realize that glutamate is a neu-
rotransmitter in part because of its abundance in brain
tissue and in part because it is at the crossroad of multiple
metabolic pathways (e.g. Erecinska and Silver 1990; Bro-
man et al. 2000; McKenna 2007; Hertz 2013). There is
5–15 mmol glutamate per kg brain tissue, depending on the
region, more than that of any other amino acid (Schousboe
1981). So although it was noted early on that glutamate
plays a central metabolic role in the brain (Krebs 1935),
that brain cells have a very high glutamate uptake activity
(Stern et al. 1949) and that glutamate has an excitatory
effect (Hayashi 1954; Curtis et al. 1959, 1960), the trans-
mitter role was not realized until the early 1980s (for
review see Fonnum 1984).
In fact, glutamate metabolism is complex and com-
partmentalized (Berl et al. 1961, 1962; Van den Berg and
Garfinkel 1971; Balcar and Johnston 1975). The important
role of glutamate uptake in the control of the excitatory
action of glutamate was recognized (Logan and Snyder
1971, 1972; Wofsey et al. 1971; Balcar and Johnston
1972). This became a hot research topic. A number of
different glutamate and aspartate analogues were synthe-
sized, and heterogeneity within glutamate uptake was
uncovered suggesting more than one uptake mechanism
(Ferkany and Coyle 1986; Robinson et al. 1991, 1993;
Fletcher and Johnston 1991; Balcar and Li 1992; Rauen
et al. 1992).
Similarly, several families of glutamate receptor pro-
teins were identified with molecular cloning (for review see
Niswender and Conn 2010; Traynelis et al. 2010; Nicoletti
et al. 2011). The receptors were classified as N-methyl-D-
aspartate (NMDA) receptors (Gonda 2012; Bonaccorso
et al. 2011; Santangelo et al. 2012), AMPA (a-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid) receptors
(Rogawski 2013), kainate receptors (Lerma and Marques
2013) and metabotropic receptors (Gregory et al. 2013).
Most, if not all, cells in the nervous system express at least
one type of glutamate receptor (Steinhauser and Gallo
1996; Vernadakis 1996; Forsythe and Barnes-Davies 1997;
Wenthold and Roche 1998; Petralia et al. 1999; Conti et al.
1999; Shelton and McCarthy 1999; Bergles et al. 2000).
The locations and functional properties of each type are
beyond the scope of this review.
Medicinal chemists continued to synthesize new com-
pounds and it is now possible to differentiate pretty well
between the various receptors and transporters. Consider-
ing the relatively large number of proteins with ability to
bind glutamate, it may seem strange that it is possible to
find compounds that can distinguish between them. The
reason is the high flexibility of the glutamate molecule
which permits several conformations that are only mini-
mally less favorable energetically at body temperature than
the lowest energy conformation (Bridges et al. 1991). This
implies that glutamate can take many shapes and explains,
in part, why the various glutamate binding proteins
(transporters, receptors, enzymes) can have quite different
binding sites and still be able to bind glutamate. A large
number of compounds are now available, and there are a
number of excellent reviews on the topic (e.g. Bra¨uner-
Osborne et al. 1997; Jensen and Bra¨uner-Osborne 2004;
Shigeri et al. 2004; Ritzen et al. 2005; Thompson et al.
2005; Bridges and Esslinger 2005; Shimamoto 2008;
Bridges et al. 2012a, b; Gregory et al. 2013; Gonda 2012;
Bonaccorso et al. 2011).
Identification of plasma membrane glutamate
transporters
A glutamate transporter, now known as EAAT2 (GLT-1;
slc1a2; Pines et al. 1992), was purified in an active form
from rat brain by employing reconstitution of transport as
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the assay to monitor the purification process (Danbolt et al.
1990). The purification was based on solubilization of rat
brain membranes with a detergent and fractionation by
conventional chromatographic techniques. This resulted in
a 30-fold increase in specific activity, but due to inactiva-
tion, the purification ratio was closer to 100-fold. It was
hard to convince ourselves that this moderate enrichment
was sufficient to yield a pure preparation, and it was even
harder to convince others. The fact that the protein tends to
give wide bands in electrophoresis gels did not make the
task any easier (see Danbolt 1994). Nevertheless, this was a
pure preparation (Levy et al. 1993; Lehre and Danbolt
1998). Antibodies were raised to the purified protein and
used to localize it in the brain (Danbolt et al. 1992; Levy
et al. 1993) and to screen expression libraries. The
sequence of the isolated cDNA predicted correctly a pro-
tein of 573 amino acids (Pines et al. 1992). Simultaneously,
but independently of each other, three other research teams
succeeded in cloning another two glutamate transporters
using completely different approaches. Storck et al. (1992)
were purifying a galactosyltransferase from rat brain and
observed that a 66 kDa hydrophobic glycoprotein copuri-
fied with this protein. The purified protein was subjected to
limited proteolysis. Partial amino acid sequences were
obtained and used for synthesizing degenerate oligonu-
cleotide probes for screening of a rat brain cDNA library.
This resulted in the identification of 543 amino acid resi-
dues long protein now referred to as EAAT1 (GLAST;
slc1a3; Storck et al. 1992). EAAT3 (EAAC1; slc1a1) was
isolated from a rabbit jejunum by Xenopus laevis oocyte
expression cloning (Kanai and Hediger 1992). The cDNA
sequence contains an open reading frame coding for a
protein of 524 amino acids. The rat brain equivalent is
89.9 % identical and 523 amino acids long (Kanai et al.
1993; Bjøra˚s et al. 1996). The three human counterparts
were quickly identified and named excitatory amino acid
transporter (EAAT)1–3 (Arriza et al. 1994). Another two
glutamate transporters were found later: EAAT4 (Fairman
et al. 1995) and EAAT5 (Arriza et al. 1997). All the EA-
ATs catalyze coupled transport of 1H?, 3Na?, and 1K?
with one substrate molecule (Klo¨ckner et al. 1993; Ze-
rangue and Kavanaugh 1996a; Levy et al. 1998; Owe et al.
2006). L-Glutamate and DL-aspartate are transported with
similar affinities while D-glutamate is not. It is important to
note that the transporters are performing exchange in
addition to net uptake. Exchange is a process whereby the
transporters exchange external and internal substrate mol-
ecules in a 1:1 relationship (see Fig. 5 in Danbolt 2001).
Thus, when transportable uptake inhibitors are added to
cell cultures, the inhibitors induce glutamate release from
the cells (e.g. Volterra et al. 1996; Danbolt 2001) Table 1.
The substrate selectivities are not reviewed here. We
will only point out (a) that the commonly used uptake
inhibitor dihydrokainate (DHK; CAS 52497-36-6) blocks
EAAT2 with high selectivity over the other EAATs (Arriza
et al. 1994; Bridges et al. 1999), and (b) that DL-threo-b-
benzyloxyaspartate (TBOA; CAS 205309-81-5) and its
variants (e.g. PMB-TBOA and TFB-TBOA) block all the
five EAATs (Bridges et al. 1999; Shimamoto 2008). These
compounds are competitive inhibitors that are not trans-
portable. This implies that they block both uptake and
exchange (for a detailed explanation, see sect. 6.5 in
Danbolt 2001). For more information, we recommend the
outstanding review by Bridges et al. (1999) as an intro-
duction and more recent reviews for the last updates (e.g.
Jensen and Bra¨uner-Osborne 2004; Shigeri et al. 2004;
Bridges and Esslinger 2005; Shimamoto and Shigeri 2006;
Shimamoto 2008; Sagot et al. 2008).
The EAAT-type of transporters also functions as chlo-
ride channels (Fairman et al. 1995; Zerangue and Kava-
naugh 1996a; Wadiche et al. 1995a, b; Ryan and Mindell
2007; Takayasu et al. 2009). EAAT4 and EAAT5 have the
largest chloride conductance (Mim et al. 2005; Gameiro
et al. 2011), and may function more as inhibitory glutamate
receptors than as transporters (Dehnes et al. 1998; Veruki
et al. 2006; Schneider et al. 2014). Arachidonic acid elicits
a substrate-gated proton current associated with the gluta-
mate transporter EAAT4 (Fairman et al. 1998; Tzingounis
Table 1 Overview of the nomenclature of plasma membrane gluta-
mate transporters
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(Arriza et al. 1997)
Glutamate transporters belong to the solute carrier (slc) family 1
(high-affinity glutamate and neutral amino acid transporter family;
Hediger et al. 2013). Although there are several proteins with ability
to transport glutamate, the term ‘‘glutamate transporter’’ is usually
used to describe the five ‘‘high-affinity glutamate transporters’’ also
called ‘‘excitatory amino acid transporters (EAATs)’’. The actual
meanings of the acronyms (GLAST glutamate–aspartate transporter,
GLT1 glutamate transporter, EAAC excitatory amino acid carrier,
EAAT excitatory amino acid transporter) are not important, as they do
not reflect functional differences among the transporters. The
nomenclature used here is the one adopted by the HUGO Gene
Nomenclature Committee (Hediger et al. 2013)
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et al. 1998). In addition, a general feature of sodium cou-
pled transport appears to be transport of water (MacAulay
et al. 2001, 2004).
Even though the mammalian transporters have not yet
been crystallized, we already know quite a lot about their
complex structure (Kanner 2007; Gouaux 2009; Kanner
2013; Vandenberg and Ryan 2013). The EAAT2 and
EAAT3 proteins are believed to be homotrimers where the
subunits are non-covalently connected (Haugeto et al.
1996). This is in agreement with studies of glutamate
transporters from Bacillus Caldotenax and Bacillus ste-
arothermophilus (Yernool et al. 2003) although crosslink-
ing studies of the mammalian transporters indicate that
there may be differences between the EAAT subtypes
(Dehnes et al. 1998). These proteins are integral membrane
proteins and they depend on the lipid environment, and are
influenced by fatty acids such as arachidonic acid (Barbour
et al. 1989; Trotti et al. 1995; Zerangue et al. 1995) and by
oxidation (Trotti et al. 1996; Trotti et al. 1998). The recent
determination of the crystall structure of a glutamate
transporter homologue (GltPh) from Pyrococcus horikoshii
(Yernool et al. 2004) and other transporters (Penmatsa and
Gouaux 2013) implies a milestone similar to the cloning of
the first transporters in the early 1990s and the generation
of knockout mice in the late 1990s. GltPh appear to be a
bowl-shaped trimer with a solvent-filled extracellular basin
extending halfway across the membrane bilayer. At the
bottom of the basin are three independent binding sites
(Yernool et al. 2004). This structure is, as uncovered
recently, ideal to facilitate rapid transport (Leary et al.
2011).
The glutamate-cystine exchanger
Another transporter that has got quite a lot of attention
lately is the so called glutamine-cystine exchanger (xCT;
slc7a11). This transporter was first described in human
fibroblasts as an electroneutral 1:1 cystine-glutamate
exchanger that carries cystine into the cell in exchange for
internal glutamate (Bannai 1986). Thus, the physiological
role of this transporter is to act as a cystine transporter that
uses the transmembrane gradient of glutamate as driving
force. It follows from this that extracellular glutamate
inhibits uptake of cystine and that uptake of cystine causes
glutamate release. The transporter responsible for this
uptake has been identified by molecular cloning (Sato et al.
1999). It is a heterooligomer consisting of two different
subunits: the 4F2hc surface antigen (slc3a2) the xCT pro-
tein (slc7a11). The substrate selectivities are excellently
reviewed by Bridges et al. (2012a, b).
There are several reasons why xCT has become a hot
topic (Conrad and Sato 2012; Lewerenz et al. 2013;
Bridges et al. 2012a, b). The first important observation
was that glioma express high levels of xCT and low
levels of EAATs suggesting that they release glutamate
and that glutamate toxicity may be a mechanism facili-
tating their invasion of normal tissue (e.g. Ye et al. 1999;
Sontheimer 2004; Takeuchi et al. 2013). Another reason
for the interest is that cystine is a source of cysteine
needed for synthesis of glutathione (Dringen 2000). There
are, however, a number of transporters that can transport
cysteine. These comprise EAAT3 (Zerangue and Kava-
naugh 1996b), the two alanine-serine-cysteine transporters
(Arriza et al. 1993; Shafqat et al. 1993; Hofmann et al.
1994), ASCT1 (slc1a4) and ASCT2 (slc1a5) as well as
several others (Bro¨er 2008). So if cystine is reduced to
cysteine at the cell surface, then cysteine can be taken up
independently of xCT. Nevertheless, xCT-deficient mice
display redox imbalance suggesting that xCT does play a
role in glutathione production (Sato et al. 2005). A third
reason for the interest in xCT is that xCT has been sug-
gested to be a major source of extracellular glutamate
(Baker et al. 2002). This has been highly controversial,
but a recent paper based on the xCT-deficient mice is
supporting the idea (De Bundel et al. 2011). There are,
however, a number of unresolved issues. The distribution
of xCT in the brain has not yet been definitively deter-
mined, and available data suggest low levels (Sato et al.
2002). If the above observations are due to direct actions
of xCT, then there must be enough xCT molecules
present to perform the proposed functions. Thus, both the
expression levels and the speed which xCT operates
(translocation cycles per second per xCT molecule) are
important to determine. As xCT is highly inducible (Sato
et al. 2001, 2004), it is should be kept in mind that
expression levels may change in stressful situations.
Finally, if xCT exchanges glutamate and cystine in a 1:1
relationship, then a massive glutamate release can only be
mediated by xCT if there is a similar transport of cystine
(or another substrate) in the other direction. In conclusion,
more work is needed before we fully understand the roles
that xCT plays.
Intracellular glutamate carriers
When glutamate enters the cytoplasm, it may undergo
further redistribution to mitochondria or synaptic vesicles
(Erecinska and Silver 1990; Nicholls 1993). (A) Mito-
chondrial glutamate transport: Several of the enzymes for
which glutamate is a substrate are located in mitochondria.
In agreement, mitochondria possess mechanisms for glu-
tamate translocation. In fact, there are four different car-
riers: AGC1 (Slc25a12; aralar1; del Arco and Satrustegui
1998), AGC2 (Slc25a13; citrin; aralar2; Kobayashi et al.
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1999; Yasuda et al. 2000), GC1 (Slc25a22; Fiermonte et al.
2002) and GC2 (Slc25a18; Fiermonte et al. 2002).
These transporters are very different from the glutamate
transporters in the plasma membranes and will not be
discussed further here (for review see Palmieri 2013).
(B) Glutamate transporters in synaptic vesicles: In gluta-
matergic nerve terminals, glutamate is carried into synaptic
vesicles by means of the so called vesicular glutamate
transporters (VGLUTs). These are also very different from
those in the plasma membrane (for review see El Mesti-
kawy et al. 2011; Omote et al. 2011) by being independent
of sodium and potassium, and by having lower affinity (km
around 1 mM). There are three different isoforms:
VGLUT1 (Slc17a7; Ni et al. 1994; Bellocchio et al. 1998,
2000; Takamori et al. 2000), VGLUT2 (Slc17a6; DNPI;
Aihara et al. 2000) and VGLUT3 (Slc17a8; Takamori et al.
2002).
Release of glutamate
Glutamate is continuously being released to the extracel-
lular fluid, and inhibition of glutamate uptake leads to
extracellular buildups of glutamate within seconds (Ja-
baudon et al. 1999). Although most of the focus has been
on synaptic release of glutamate from nerve terminals by
exocytosis of synaptic vesicles, this is not the only mech-
anism able to supply the extracellular fluid with glutamate
(Danbolt 2001). In fact, there are several different non-
vesicular (non-exocytotic) mechanisms that appear to be
important. One is through anion channels (Kimelberg et al.
1990; Kimelberg and Mongin 1998; Wang et al. 2013) and
another is via reversed operation of the glutamate trans-
porting proteins at the plasma membrane (e.g. Levi and
Raiteri 1993; Longuemare and Swanson 1995; Roettger
and Lipton 1996; Jensen et al. 2000; Rossi et al. 2000;
Jabaudon et al. 2000; Sontheimer 2008). A third is via xCT
as explained above. A fourth mechanism that has been
vividly debated over the last decade is whether mature
brain astrocytes in situ also have the ability to release
glutamate by exocytosis (Bezzi et al. 2004). The differ-
ences in opinions can to some extent be explained by the
use of different model systems. For instance, primary
astrocytes in culture differ from mature astrocytes in the
brain (Cahoy et al. 2008) so observations from cultures are
not necessarily valid for the intact living brain. Neverthe-
less, it seems likely that also mature astrocytes in situ may
release glutamate (Malarkey and Parpura 2008; Nederg-
aard and Verkhratsky 2012; Wang et al. 2013), but exo-
cytosis of vesicles similar to those in nerve terminals is
questionable (Hamilton and Attwell 2010). In fact, a recent
paper refutes the notion that astrocytes express vesicular
glutamate transporters (Li et al. 2013). Thus, this does not
entirely rule out the concept of gliotransmitters because
glutamate may be released via other mechanisms as
explained above, but it does suggest critical evaluation of
the literature.
Regulation of the EAAT-type of transporters
Considering the importance of the glutamate transporters,
pharmacological manipulation of transporter function may
prove to be highly interesting from a therapeutic point of
view (Sheldon and Robinson 2007). Although there are
several examples where dysregulation of transporters
contributes to the pathogenetic process, there are few
examples of transporters being the primary cause (e.g.
Danbolt 2001; Sattler and Rothstein 2006; Lauriat and
Mcinnes 2007; Bro¨er and Palacin 2011). For instance, it is
clear that complete absence of EAAT2 results in sponta-
neous epilepsy (Tanaka et al. 1997) and increased extra-
cellular glutamate (Mitani and Tanaka 2003; Takasaki
et al. 2008), but studies of humans with epilepsy have not
uncovered any direct link to glutamate transporter expres-
sion (Tessler et al. 1999; Akbar et al. 1997; Bjørnsen et al.
2007). Nevertheless, studies from knockout mice and from
humans with mutated transporters show links to disease
(for a recent short update see Zhou and Danbolt 2013).
Consequently, uncovering regulatory mechanisms is
something that has been a hot topic and has interested a
large number of researchers. A full account is beyond the
scope of this review. Here we only mention a few points.
The first observation revealing regulation of glial glu-
tamate transporter expression came from lesion experi-
ments (Levy et al. 1995). Unilateral ablation of the
neocortex in young adult rats resulted in ipsilateral down
regulation of EAAT1 and EAAT2 in the striatum. The
lesions did not penetrate the corpus callosum so striatum
was not directly affected. However, the neocortical lesion
eliminated the cell bodies that are responsible for the
corticostriatal axons resulting in a loss of glutamatergic
terminals in the striatum. Because astrocytes reduced their
levels of EAAT1 and EAAT2 in response to the removal of
these terminals, it was assumed that neuro-glia interactions
were important in the regulation of transporter expression
(Levy et al. 1995). This was followed up in cell cultures.
Astrocytes cultured in the absence of neurons hardly
expressed EAAT2 at all, while addition of neuron condi-
tioned medium turned on EAAT2 expression (e.g., Gege-
lashvili et al. 1996, 1997, 2000, 2001; Plachez et al. 2000).
This regulation turned out to be via several different
pathways. Further, glutamate transporters are regulated by
protein kinase C (Casado et al. 1993; reviewed by: Gonz-
alez and Robinson 2004; Vandenberg and Ryan 2013), by
zinc (Vandenberg et al. 1998; Mitrovic et al. 2001;
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Vandenberg and Ryan 2013), and by arachidonic acid as
mentioned above. In fact, there is regulation on more or
less all levels from transcription to posttranslational mod-
ification and trafficking (for review see Seal and Amara
1999; Bergles et al. 1999; Hediger 1999; Kullmann 1999;
Sims and Robinson 1999; Danbolt 2001; Robinson 2006;
Sattler and Rothstein 2006). The most exciting discovery
so far from a drug development point of view is the finding
that beta-lactam antibiotics, e.g. Ceftriaxone, increase
EAAT2 expression (Rothstein et al. 2005; Berry et al.
2013). Another team has also started high-throughput
screening in order to identify translational activators of
glial glutamate transporter EAAT2 (Colton et al. 2010) and
have identified some pyridazine derivatives that may serve
as lead compounds for drug development (Xing et al.
2011). Another interesting finding is a spider toxin that
enhances EAAT2 transport activity (Fontana et al. 2007),
but the compound responsible has not yet been identified.
Approaches used to localize glutamate transporters
Early attempt to localize glutamate uptake sites were done
using autoradiography in combination with tissue slices or
synaptosome preparations (e.g. Minchin and Beart 1975;
McLennan 1976; Beart 1976; Storm-Mathisen 1981;
Storm-Mathisen and Wold 1981). To obtain higher reso-
lution, thinner sections were needed. By using dry mount
autoradiography (Young and Kuhar 1979; Danbolt et al.
1993) in combination with ‘‘sodium-dependent binding’’ of
excitatory amino acids the uptake sites (for references see
Danbolt 1994), higher resolution seemed to be within
reach. However, heteroexchange complicated the inter-
pretations as the amount of retained radioactively labeled
ligand was dependent on both the number of transporter
molecules and by the amount of endogenous dicarboxylic
amino acid trapped within the membranes (Danbolt and
Storm-Mathisen 1986a, b; Danbolt 1994).
From the early days of glutamate research, it was believed
that glutamate is taken up by glutamatergic nerve terminals
(Fonnum 1984), but the finding that glial glutamate trans-
porters are down-regulated after glutamatergic denervation
(Levy et al. 1995), weakened the evidence (for a discussion,
see sect. 4.2 in Danbolt 2001). By incubating tissue slices in
D-aspartate and fixing the slices, it was possible to detect
fixed D-aspartate with antibodies. With this technique,
uptake in both astrocytes and nerve terminals was demon-
strated at the electron microscopic level (Gundersen et al.
1993). D-aspartate is often used instead of L-glutamate as a
probe for glutamate uptake because it is slowly metabolized
in brain tissue (Davies and Johnston 1976).
After the protein sequences of the transporters were
known, synthetic peptides could be used to generate
antibodies to the transporters themselves (Danbolt et al.
1998) rather than to the substrates. This led to an explosion
in the use of antibodies to transporters, but, unfortunately,
not all investigators validated their antibodies and proce-
dures well enough (for detailed discussion see Holmseth
et al. 2005, 2006, 2012a). The most difficult part is to obtain
good negative controls. Antibodies may react with seem-
ingly unrelated proteins (Holmseth et al. 2005; Zhou et al.
2014). In fact, antibody binding can always be achieved
(see for instance Fig. 3 in: Holmseth et al. 2005). This is just
a question of adjusting the assay conditions. Without a good
negative control (e.g. tissue from knockout mice processed
in parallel with tissue from wild-type mice), it is not pos-
sible to prove that the binding is to the antigen of interest.
Therefore, antibody binding does not in itself prove that a
given antigen is present. In this context it should be noted
that the so called pre-adsorption test can easily give a false
impression of specificity (Holmseth et al. 2012a). Whenever
possible, it is a good idea to use additional methods,
including in situ hybridization and Western blotting in
combination with immunocytochemistry. TaqMan Real
Time PCR is an excellent method for getting a first
approximation of expression levels (e.g. Lehre et al. 2011;
Zhou et al. 2012a). Another approach is to search available
transcriptome and proteome datasets. For instance, prote-
ome data from rat proximal tubules (http://dir.nhlbi.nih.
gov/papers/lkem/pttr/) confirms the presence of EAAT3,
but does not confirm expression of any of the other EAATs.
Similarly, EAAT2 is in liver, but the other EAATs were not
detected (http://141.61.102.16/), and neither the EAATs nor
the VGLUTs were detected by proteome analysis of mouse
pancreas (Zhou et al. 2014). Together, these data cast doubt
over a large number of immunocytochemistry reports. The
reason is obvious. Labeling with antibodies can always be
obtained, and without good negative controls, it is not
possible to tell if the labeling represents the antigen of
interest or artifacts (see Holmseth et al. 2012a). Further,
rapid post mortem proteolysis represents and additional
challenge when studying human samples (Beckstrøm et al.
1999; Tessler et al. 1999; Li et al. 2012). Also note that
water soluble proteins present in the samples may inhibit
binding of transporters to the blotting membranes (Zhou
et al. 2012b). Thus, strong upregulation of other proteins
should be considered a potential source of error when
estimating transporter levels by immunoblotting. Electron
microscopy in combination with pre-embedding immuno-
cytochemistry without detergents on unfrozen tissue is ideal
for identification of labeled cell types, but is not ideal for
subcellular distribution as the peroxidase reaction product
diffuses some distance before precipitating. (Depending on
the strength of the reaction, the reaction product may diffuse
a couple of hundred nanometers.) In contrast, post-embed-
ding immunogold is better for collecting semi-quantitative
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data and gives better intracellular resolution, but when cell
membranes are labeled and cells are close to each other as
they typically are in the brain, then immunogold cannot tell
which membrane labeling belongs to (for description of
these methods, see Danbolt et al. 1998; Amiry-Moghaddam
and Ottersen 2013). Another problem with post-embedding
immunogold is that there must be a sufficient number of
target molecules in the plane of the section. This is case for
EAAT1, EAAT2 and EAAT4. These proteins are present at
very high concentrations (Dehnes et al. 1998; Lehre and
Danbolt 1998) making them ideal targets for immunogold
investigations. This explains, in part, why our early locali-
zation studies were so successful (Chaudhry et al. 1995;
Dehnes et al. 1998). In contrast, EAAT3 is expressed at
lower levels resulting in too few molecules per micrometer
plasma membrane length to distinguish real labeling from
background noise (Holmseth et al. 2012b). It should be
recalled that the tissue sections used for electron micros-
copy are thin (40–60 nm) and thereby only slightly thicker
than the outer diameter of synaptic vesicles (40 nm), and
only two/three times thicker than the width of the synaptic
cleft (20 nm). The antibodies do not penetrate well into the
sections. To maximize labeling, the section may be moun-
ted so that they can be labeled on both sides. Thus, the
sensitivity of the post-embedding immunogold technique is
limited by the number of proteins in the exact section plane.
Another challenge follows from the vulnerability of the
sections and thereby also the labeling. These sections are
easily damaged during processing. Consequently, there is
variability and this leads to another challenge: avoiding
sampling error. This challenge comes in addition to those
mentioned above (specificity, proteolysis, etc.).
It is also important to consider if any detected proteins
are expressed at physiologically relevant levels. The
number of molecules needed to accomplish a given task
depends on what that task is. This consideration is partic-
ularly relevant for neurotransmitter transporters because
the transport process is fairly slow. The cycling time of
EAAT2 and EAAT3 are in the order of 30 glutamate
molecules per second at Vmax (Otis and Jahr 1998; Otis
and Kavanaugh 2000; Bergles et al. 2002; Grewer and
Rauen 2005) and EAAT5 is even slower (Gameiro et al.
2011). The cycling time of the GABA transporters appear
to be comparable to those of the EAATs (Mager et al.
1993; Sacher et al. 2002; Karakossian et al. 2005; Gonzales
et al. 2007). This means that the number of transporters
must be high. There is a rapid extracellular turnover of
glutamate (Jabaudon et al. 1999), and despite this, the
resting levels of extracellular glutamate in normal brains
are low, possibly as low as 25 nm (Herman and Jahr 2007).
Because the km-values are about 1,000 times higher
(Danbolt 2001), maintenance of such low extracellular
levels implies a vast excess of transporter proteins (Bergles
and Jahr 1997; Dehnes et al. 1998; Lehre and Danbolt
1998; Otis and Kavanaugh 2000).
Cellular and subcellular distribution of glutamate
transporters in normal mature brain tissue
A large number of papers on transporter distributions have
been published, and it is not easy to navigate in the literature
as many of the statements are corrected in later publica-
tions. Figure 1 is a schematic illustration of the distributions
of EAAT1, EAAT2 and EAAT3 in the forebrain.
EAAT1 (GLAST; slc1a3) is selectively expressed in
astrocytes throughout the CNS (Lehre et al. 1995). This
conclusion is supported both by in situ hybridization and
immunocytochemistry (e.g. Ginsberg et al. 1995; Rothstein
et al. 1995 Schmitt et al. 1997; Berger and Hediger 1998,
2000) and appears to be valid for all parts of the central
nervous system including the regions where EAAT1 is the
predominant transporter (Lehre et al. 1995; Lehre and
Danbolt 1998; Takatsuru et al. 2007; Takayasu et al. 2009):
the retina (Rauen et al. 1996; Lehre et al. 1997; Rauen et al.
Fig. 1 A schematic illustration of glutamate transporter distributions
around synapses close to a blood vessel in the hippocampus. Four
glutamatergic nerve terminals (T) are shown forming synapses onto
dendritic spines (S). Astrocyte branches are indicated (G). Note that
astrocytes have very high densities (Lehre et al. 1995; Ginsberg et al.
1995; Lehre and Danbolt 1998) of both EAAT2 (red dots) and
EAAT1 (blue dots). The highest densities of EAAT1 and EAAT2 are
in the astrocyte membranes facing neuropil, while the membranes
facing the endothelium have low levels. Also note that glutamate
transporters have not been detected in the endothelium. EAAT1 is
selective for astrocytes (Lehre et al. 1995; Ginsberg et al. 1995),
while EAAT2 is predominantly expressed in astrocytes (Danbolt et al.
1992), but there is also some (about 10 %) in hippocampal nerve
terminals (Furness et al. 2008). EAAT3 (green dots) is selective for
neurons, but is expressed at levels two orders of magnitude lower than
EAAT2 and is targeted to dendrites and cell bodies (Holmseth et al.
2012b). Also note that the endfeet may actually overlap with no gaps
in between them (Mathiisen et al. 2010) (Copyright: Neurotransporter
AS; Reproduced with permission)
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1998; Rauen 2000; Rauen and Wiessner 2000), the inner
ear (Furness and Lehre 1997; Takumi et al. 1997), and the
circumventricular organs (Berger and Hediger 2000). Thus,
there is no disagreement here. Other statements can be
found in the literature, but these have been corrected by the
authors themselves.
After having determined the cell types expressing
EAAT1 (Lehre et al. 1995), immunogold was performed to
obtain additional information (Chaudhry et al. 1995). This
revealed that EAAT1 is preferentially targeted to the
plasma membranes, and that plasma membranes facing
neuropil have higher densities than those facing cell bodies,
pia mater and endothelium (Fig. 1).
Mice lacking EAAT1 (Watase et al. 1998) develop
normally, but show symptoms of insufficient glutamate
uptake in regions where EAAT1 is the major glutamate
transporter (Watase et al. 1998; Hakuba et al. 2000; Harada
et al. 1998). The EAAT1 knockout mice also display poor
nesting behavior; abnormal sociability, reduced alcohol
intake and reward (Watase et al. 1998; Stoffel et al. 2004;
Karlsson et al. 2009, 2012). Lack of GLAST does not lead
to spontaneous seizures like those seen in connection with
EAAT2-deficiency (Tanaka et al. 1997), but GLAST
deficiency increases seizure duration and severity (Wa-
tanabe et al. 1999). EAAT1 mutations in humans are linked
to episodic ataxia (Bro¨er and Palacin 2011; Jen et al. 2005;
de Vries et al. 2009).
EAAT2 (GLT-1; slc1a2) was the first glutamate trans-
porter to be localized immunocytochemically. In the
mature and normal brain it is predominantly expressed in
astrocytes (Danbolt et al. 1992; Levy et al. 1993; Rothstein
et al. 1994; Lehre et al. 1995). There is no disagreement
here either, and this conclusion is supported both by later
immunocytochemistry (e.g. Schmitt et al. 1996; Kugler and
Schmitt 2003; Berger et al. 2005; Holmseth et al. 2009) and
in situ hybridization (Torp et al. 1994, 1997; Berger and
Hediger 2000, 2001) as well as by data obtained with
EAAT2 eGFP BAC reporter mice (de Vivo et al. 2010a).
EAAT2 is the only one of the EAAT-type of glutamate
transporters that is required for survival under non-chal-
lenging conditions (Tanaka et al. 1997; Danbolt 2001).
This is in agreement with biochemical data showing that
the EAAT2 protein represents about 1 % of the total
forebrain protein and that it is about four times more
abundant than EAAT1 in the hippocampus and six times
less abundant than EAAT1 in the cerebellum (Lehre and
Danbolt 1998). Based on immunoadsorption of transport
activity EAAT2 was shown to account for 95 % of the total
glutamate uptake activity in young adult forebrain tissue
(Danbolt et al. 1992; Haugeto et al. 1996). This conclusion
was confirmed by deletion of the EAAT2 gene in mice
(Tanaka et al. 1997; Voutsinos-Porche et al. 2003;
Matsugami et al. 2006; Kiryk et al. 2008; Holmseth et al.
2012b) as well as by electrophysiological recordings of
glutamate transporter currents (Otis and Kavanaugh 2000).
The discussion about EAAT2 distribution concerns
expression in neurons. Having said that, there is con-
sensus that EAAT2 is expressed in cultured neurons
from hippocampus and neocortex; in particular if these
are cultured in the absence of astrocytes (Mennerick
et al. 1998; Wang et al. 1998; Plachez et al. 2000) in
agreement with observations that EAAT2 is transiently
localized on growing axons of the mouse spinal cord
before establishing astrocytic expression (Yamada et al.
1998). There is also consensus that EAAT2 is present in
neurons in the normal and mature mammalian retina
(Rauen et al. 1996, 1999; Rauen and Kanner 1994; Euler
and Wassle 1995; Rauen 2000).
The controversy is related to expression of EAAT2 in
neurons in the normal and mature brain (cerebrum and
cerebellum). All studies, however, agree that there is
EAAT2 mRNA in CA3 hippocampal neurons (Torp et al.
1994, 1997; Berger and Hediger 2000, 2001; de Vivo et al.
2010a) and that their axon-terminals express the protein, at
least in the CA1 (Chen et al. 2004; Furness et al. 2008;
Melone et al. 2009, 2011). Further, all of the glutamate
uptake activity in glutamatergic terminals in CA1 is due to
EAAT2 (Furness et al. 2008).
The remaining controversy concerns (a) the expression
of EAAT2 in axon-terminals in other parts of the brain,
and (b) the physiological importance of the uptake into
terminals. Why was about half of all D-aspartate taken
up by hippocampus slices found in axon-terminals when
terminals only contain around 10 % of the EAAT2
protein (Furness et al. 2008)? This disproportionally
large uptake cannot simply be disregarded as an in vitro
artifact due to a higher rate of heteroexchange than net
uptake (Zhou et al. 2013), but it might still be an artifact
because the possibility has not been ruled out that
astrocytes release glutamate via anion channels or simi-
lar. Preliminary data from selective deletion of EAAT2
in axon-terminals indicate disturbances in synaptic
transmission (Sun et al. 2012), and thereby may suggest
that EAAT2 in terminals is functionally relevant. How-
ever, further studies are required before definite conclu-
sions can be made.
In contrast to EAAT1, there is very little EAAT2 in
mice and rats at birth and in the first postnatal week (Ul-
lensvang et al. 1997; Furuta et al. 1997). This explains why
EAAT2-knockout mice are inconspicuous at birth. But at
3 weeks, when the EAAT2-levels in wild-type mice have
increased to 50 % of adult levels, the EAAT2-deficient
mice can readily be identified because they are hyperactive,
epileptic and smaller than their wild-type littermates. They
have increased extracellular glutamate levels (Mitani and
Tanaka 2003; Takasaki et al. 2008), and about half of them
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die from spontaneous seizures before they reach 4 weeks of
age (Tanaka et al. 1997). The heterozygote EAAT2
knockout mice (±) have only half the EAAT2-concentra-
tions as wild-type mice, but do not show any apparent
morphological brain abnormalities (Kiryk et al. 2008), but
are more vulnerable to traumatic spinal cord injury (Lepore
et al. 2011).
EAAT3 (EAAC1; slc1a1) has been particular hard to
localize. Nevertheless, the first studies were basically cor-
rect (Kanai and Hediger 1992; Rothstein et al. 1994).
EAAT3 is a neuronal transporter, and is not expressed in
glial cells (Holmseth et al. 2012b; Shashidharan et al.
1997). It appears to be expressed in the majority if not all
neurons throughout the CNS, but has a unique sorting motif
(Cheng et al. 2002) selectively targeting it to somata and
dendrites avoiding axon terminals (Holmseth et al. 2012b;
Shashidharan et al. 1997).
The highest levels of EAAT3 in the brain are found in the
hippocampus and neocortex, but the total tissue content in
young adult rat brains is about 100 times lower than that of
EAAT2 (Holmseth et al. 2012b). It is also expressed in the
kidney and in the ileum. In agreement, mice lacking EAAT3
(Peghini et al. 1997) develop dicarboxylic aminoaciduria,
but do not show signs of neurodegeneration at young age and
do not have epilepsy (Peghini et al. 1997; Aoyama et al.
2006; Berman et al. 2011). Humans lacking EAAT3 develop
dicarboxylic aminoaciduria (Bailey et al. 2011) and EAAT3
polymorphisms are associated with obsessive–compulsive
disorders (Brandl et al. 2012; Walitza et al. 2010).
EAAT4 (slc1a6) is predominantly found in the cere-
bellar Purkinje cells (Fairman et al. 1995; Dehnes et al.
1998) where it is targeted to the dendrites, the spines in
particular (Dehnes et al. 1998), but there is also some
EAAT4 in a subset of forebrain neurons (Dehnes et al.
1998; Massie et al. 2008; de Vivo et al. 2010b) and in
vestibular hair cells and calyx endings (Dalet et al. 2012).
EAAT4 knockout mice are viable and appear normal
(Huang et al. 2004) albeit with some alteration of receptor
activation (Nikkuni et al. 2007).
EAAT5 (slc1a7) is preferentially expressed in the
retina, while the levels in the brain are low (Arriza et al.
1997; Eliasof et al. 1998). EAAT5 is also expressed in
vestibular hair cells and calyx endings (Dalet et al.
2012). There is more than one isoform in the retina due
to variable splicing (Eliasof et al. 1998). As explained
above, EAAT4 and EAAT5 are not very efficient as
transporters, but are efficient chloride channels suggest-
ing that they may be more important as inhibitory glu-
tamate receptors than as transporters. Some investigators
have tried to determine the exact cellular and subcellular
localization of EAAT5, but the validity of these studies
is hard to judge at present because nobody has as yet
made an EAAT5 knockout mouse that could serve as
negative control for validation of the immunolabeling.
We have previously shown how important this control is
and also how inadequate the so called pre-adsorption test
is (Holmseth et al. 2012a). So, validated information on
EAAT5 distribution remains to be provided.
Comments on the glutamine-glutamate cycle
Glutamate taken up by astroglial cells can be metabolized
via the tricarboxylic acid cycle and be used in protein
synthesis or converted to glutamine. Glutamine can be
released to the extracellular fluid by a sodium neutral
amino transporter in the astrocytic membrane by SNAT3
(Boulland et al. 2002, 2003; Mackenzie and Erickson 2004;
Nissen-Meyer et al. 2011) and SNAT5 (SN2; slc38a5)
(Hamdani et al. 2012) because it is inactive in the sense
that it cannot activate glutamate receptors (for review:
Erecinska and Silver 1990; Danbolt 2001; Hertz 2013). The
conversion of glutamate to glutamine is catalyzed by the
enzyme glutamine synthetase (GLUL) in an ATP-depen-
dent manner (Erecinska and Silver 1990; Marcaggi and
Coles 2001). Glutamine synthetase plays important roles in
the brain and in other organs from implantation to high age.
This is evident from studies of glutamine deficiency in man
and mice (He et al. 2007, 2010a, b; Haberle et al. 2011,
2012). Further, reduced glutamine synthetase levels are
associated with some forms of epilepsy (Eid et al. 2004).
The prevailing view has been that glutamine from
astrocytes is the predominant source of glutamate in
glutamatergic terminals (Sibson et al. 2001; Hertz 2013),
but this hypothesis implies that the supply of glutamine to
terminals keeps up with glutamate release. And although
there are many observations in cultured cells suggesting the
existence of glutamine transporters in glutamatergic ter-
minals, it is important to keep in mind that cultured astro-
cytes are different from mature astrocytes (e.g. Plachez
et al. 2000; Cahoy et al. 2008). Further, it is important to
note that glutamine transporters have so far not been posi-
tively identified in terminals in brain tissue (Mackenzie and
Erickson 2004; Chaudhry et al. 2002; Conti and Melone
2006). The only positive identifications of SNAT2 (SAT2;
slc38a2) and SNAT1 (SAT1; GlnT; slc38a1) are in den-
drites and cell bodies of neurons (e.g. Jenstad et al. 2009;
Solbu et al. 2010; Conti and Melone 2006). One possibility
is that they have evaded detection in glutamatergic termi-
nals due to methodological challenges. Another possibility
is that they have not been detected simply because they are
not there. This would be in line with studies suggesting that
SNAT1 and SNAT2 play no role in delivering glutamine for
glutamatergic transmission (Grewal et al. 2009). There
could be other glutamine transporters, however. For
instance, ASCT2 (slc1a5) has ability to transport glutamine
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(Bro¨er et al. 1999), but is expressed at low levels in the
mature brain (Utsunomiya-Tate et al. 1996; Bro¨er and
Brookes 2001). There are also other potential candidates
within the slc38-family. On the other hand, lack of signif-
icant glutamine uptake activities in terminals would be is in
line with some old reports (e.g. Hertz et al. 1980; Yu and
Hertz 1982; McMahon and Nicholls 1990). Another pos-
sibility is whether glutamate may be formed in a glutamine-
independent manner (Hassel and Bra˚the 2000; McKenna
et al. 2000), but this is also debated. A third source is direct
uptake by glutamate transporters in terminals themselves
(Gundersen et al. 1993). As explained above, there is
EAAT2 in terminals and this uptake is highly active (Fur-
ness et al. 2008). Another complicating factor is that nerve
terminals in different brain regions may differ. While ter-
minals in several forebrain regions (e.g. neocortex, hippo-
campus and striatum) have been shown to posses glutamate
uptake activity (e.g. Gundersen et al. 1993), this is more
uncertain in the cerebellar cortex (e.g. Wilkin et al. 1982).
In conclusion, the glutamine-glutamate cycle has been
studied and debated for about 50 years and we still do not
have the final answer!
Glutamate transporters at the blood brain barrier
The nervous system isolates itself from blood by means of
barriers (e.g. Abbott 2005; Alvarez et al. 2013). This is
important for a number of reasons. One of them is the fact
that serum glutamate is typically in the range 50–200 lm
(Zlotnik et al. 2011a, b, c) which is orders of magnitude
higher than the concentrations that are toxic to neurons
(Danbolt 2001).
The blood–brain barrier is between blood and the
interstitial fluid of the brain. It is in mammals formed by
the endothelial cells after influence from brain cells.
Another barrier is in the choroid plexus epithelium which
secretes cerebrospinal fluid (CSF). These barriers are
important both from a physiological point of view because
they are essential for brain homeostasis, and from a phar-
macological point of view because they prevent drugs from
entering brain tissue (Deboer and Gaillard 2007; Teichberg
2007). The literature is extensive and full of conflicting
reports. A full account is beyond the scope of this review.
Here we only want to point out (Fig. 1) that brain barrier
endothelial cells do not express significant levels of
EAAT1-3 (Lehre et al. 1995; Berger and Hediger 2000;
Holmseth et al. 2009, 2012b). There are, however, huge
amounts of glutamate transporters in the astrocytic endfeet
surrounding the blood vessels (Fig. 1). When isolating
brain microvessels, the preparations are likely to be con-
taminated by endfeet and this may explain some of the
data. Thus, it seems that no significant transport of
glutamate can occur through a normal and intact blood–
brain barrier. In agreement, injection of radiolabeled glu-
tamate and aspartate does not result in accumulation of
radioactivity in the brain (Klin et al. 2010). On the other
hand, there is an efflux mechanism for glutamate as blood-
mediated scavenging is reported to reduce glutamate in the
cerebrospinal fluid (Gottlieb et al. 2003). There is some
evidence that this may offer some protection (Zlotnik et al.
2008; Teichberg et al. 2009; Zlotnik et al. 2010; Nagy et al.
2010). The mechanism, however, of release from the brain
remains to be identified. This illustrates that brain water
homeostasis and transport mechanisms between the blood
and the extracellular fluid in brain are incompletely
understood. Recent work from Nedergaard and co-workers
may represent a leap in our understanding. They introduce
the term ‘‘glymphatics’’ (Iliff et al. 2012; Nedergaard 2013)
to describe flow of fluid from the arachnoid space along
blood vessels into brain tissue. This may reconcile a
number of apparently conflicting reports. Perhaps this also
will explain why the betaine-GABA transporter (BGT1;
slc6a12; Zhou et al. 2012b) and the taurine transporting
GABA transporter 2 (GAT2; slc6a13; Zhou et al. 2012a)
are expressed in the leptomeninges.
Concluding remarks
As outlined above, substantial progress has been made over
the last decades. But there are major gaps in our under-
standing of key processes. One example is transport of
metabolites across the blood brain barrier. Another
unknown is the uptake in glutamatergic nerve endings and
the relevance of the glutamate-glutamine cycle for trans-
mitter glutamate. A third topic is why the body needs
several different glutamate transporters, and how they can
be pharmacologically modulated.
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